Pioneering work from the Schreiber group using either IFN-γ blocking antibodies [89] or mouse models lacking essential IFN-γ signaling molecules [90] provided compelling evidence on a pivotal role of the IFN-γ signaling in cancer immunosurveillance. The gene discussed is IFNG; the disease is cancer.